PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma

BACKGROUND: Current therapeutic management of advanced melanoma patients largely depends on their BRAF mutation status. However, the vast heterogeneity of the tumors hampers the success of therapies targeting the MAPK/ERK pathway alone. Dissecting this heterogeneity will contribute to identifying ke...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrales, Eyleen, Levit-Zerdoun, Ella, Metzger, Patrick, Mertes, Ralf, Lehmann, Ariane, Münch, Julia, Lemke, Steffen, Kowar, Silke, Boerries, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700886/
https://www.ncbi.nlm.nih.gov/pubmed/36434616
http://dx.doi.org/10.1186/s12964-022-00989-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700886/
https://www.ncbi.nlm.nih.gov/pubmed/36434616
http://dx.doi.org/10.1186/s12964-022-00989-y

Ejemplares similares